Prana: Quintiles Makes Second Investment in Prana of $1M

Prana Biotechnology Limited PRAN announced today that leading global clinical research provider Quintiles will purchase shares in Prana for a total subscription of US$1,000,000. The funding will be used in support of Prana's recently announced business strategy to accelerate the clinical development of PBT2 through Phase II trials of Huntington's Disease and Alzheimer's Disease to be initiated this year.